News and Announcements
Keeping Up With Investors’ Expectations
- Published December 19, 2022 7:38AM UTC
- Publisher Osama Hassan
- Categories Capital Raising Tips
I just went through a report published by Goodx entitled, “Angel Investor’s Thoughts On Startup Exit”. This particular graph caught my attention.
It clearly illustrates that investors tend to have very high expectations of required returns when investing in pre-seed and seed rounds in particular.
The inherent risk posed to investors is one of the main reasons behind why 9 out of 10 startups fail to raise pre-series A funding.
What does this mean for founders? It highlights that fundraising takes more time than you think and that consistent communication is important in convincing investors.
Though my observations were slightly besides the point of the report (the report is on startup exists) I thought it worth sharing.
You can access the full report from the link in the comments section below 👇
Click here to view the original Linkedin post.
Looking for a platform to raise capital? Click here to discover how Wholesale Investor can help you.
Your capital engagement platform
With a 14-year track record, a network of 32,000+ investors, and a capital raising platform, Wholesale investor is a leading investment platform for start-ups, scale-ups, emerging growth companies, and small caps.
Capital Raising Tips
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
